COSMOS Pharmaceutical Corporation

As of May 31, 2025, COSMOS Pharmaceutical Corporation carries a market capitalization of 700.00B, placing it among publicly traded companies globally. Its enterprise value stands at 692.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

COSMOS Pharmaceutical Corporation's next confirmed earnings release is scheduled for January 8, 2027.

As of May 31, 2025, COSMOS Pharmaceutical Corporation has 79.26M shares outstanding.

These figures are as of May 31, 2025.

As of May 31, 2025, COSMOS Pharmaceutical Corporation maintains a current ratio of 0.75, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended May 31, 2025.

Over the twelve months ended May 31, 2025, COSMOS Pharmaceutical Corporation recorded 681.00M in income tax expense.

As of the close on October 22, 2026, COSMOS Pharmaceutical Corporation's stock has declined approximately 14.39% over the past 52 weeks. The 50-day moving average sits at 6,452.28, while the 200-day moving average is 6,562.76.

As of May 31, 2025, COSMOS Pharmaceutical Corporation holds 57.04B in cash and equivalents against 49.96B in total debt, resulting in a net debt position of -14.15B. Total book value stands at 257.46B, with working capital of -55.06B providing operational flexibility.

COSMOS Pharmaceutical Corporation's most recent stock split took place on August 29, 2024 with a 1:2 split ratio.